{"entity":{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","aka":[],"tldr":"Principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive gastric cancer, and a founder of Korean phase 1 oncology.","summary":"Yung-Jue Bang is Professor Emeritus of Internal Medicine at the Seoul National University Cancer Research Institute and Seoul National University Hospital. He was principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive advanced gastric cancer, and a founder of Korean phase 1 oncology, leading a long series of first-in-human and phase 1 studies including early testing of PD-1 antibodies and PARP inhibitors in gastric cancer. His publications include the ToGA trial of trastuzumab with chemotherapy against chemotherapy alone in HER2-positive gastric or gastro-oesophageal junction cancer. He mentored much of Korea's medical oncology leadership.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bang%20YJ%5BAuthor%5D%20gastric%20cancer%20Seoul%20National%20University"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["her2","pd1"],"drugs":["trastuzumab"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":["toga"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor Emeritus of Internal Medicine; Seoul National University Cancer Research Institute","institutionId":"snuh","specialisms":["Gastric cancer","HER2","Early-phase drug development","Immunotherapy"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bang%20YJ%5BAuthor%5D%20gastric%20cancer%20Seoul%20National%20University"}],"papers":[{"title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)","journal":"Lancet","year":2010,"doi":"10.1016/S0140-6736(10)61121-X"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"}],"orcid":"0000-0001-6000-4597"},"route":"/people/bang-yung-jue/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/"}],"trial":[{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/"}],"paper":[{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/"},{"id":"paper-toga-trastuzumab-gastric-lancet-2010","kind":"paper","name":"ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer","route":"/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/"}]}}